Haferlach C - Search Results

1

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia.

Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, Ghetti M, Stengel A, Guadagnuolo V, De Tommaso R, Papayannidis C, Robustelli V, Franchini E, Rorà AGLD, Ferrari A, Fontana MC, Bruno S, Ottaviani E, Soverini S, Storlazzi CT, Haferlach C, Sabattini E, Testoni N, Iacobucci I, Huntly BJP, Ficarra E, Martinelli G. Padella A, et al. Among authors: haferlach c. Cancers (Basel). 2019 Dec 5;11(12):1951. doi: 10.3390/cancers11121951. Cancers (Basel). 2019. PMID: 31817495 Free PMC article.

2

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B. Haferlach C, et al. Among authors: haferlach t. Blood. 2009 Oct 1;114(14):3024-32. doi: 10.1182/blood-2009-01-197871. Epub 2009 May 8. Blood. 2009. PMID: 19429869 Free article.

3

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Blood. 2014 Jul 10;124(2):251-8. doi: 10.1182/blood-2014-02-558833. Epub 2014 May 14. Blood. 2014. PMID: 24829203 Free article.

4

Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.

Stengel A, Kern W, Zenger M, Perglerová K, Schnittger S, Haferlach T, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Genes Chromosomes Cancer. 2016 Jan;55(1):82-94. doi: 10.1002/gcc.22313. Epub 2015 Oct 23. Genes Chromosomes Cancer. 2016. PMID: 26493028

5

The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Genes Chromosomes Cancer. 2016 Oct;55(10):777-85. doi: 10.1002/gcc.22377. Epub 2016 Jul 4. Genes Chromosomes Cancer. 2016. PMID: 27218649

6

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.

Haferlach T, Weber S, Konietschke R, Nadarajah N, Stengel A, Kern W, Haferlach C, Meggendorfer M. Haferlach T, et al. Among authors: haferlach c. Leukemia. 2016 Oct;30(10):2123-2125. doi: 10.1038/leu.2016.156. Epub 2016 May 25. Leukemia. 2016. PMID: 27220669 No abstract available.

7

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Leukemia. 2017 Mar;31(3):705-711. doi: 10.1038/leu.2016.263. Epub 2016 Sep 29. Leukemia. 2017. PMID: 27680515

8

MYC rearranged B-cell neoplasms: Impact of genetics on classification.

Haberl S, Haferlach T, Stengel A, Jeromin S, Kern W, Haferlach C. Haberl S, et al. Among authors: haferlach t, haferlach c. Cancer Genet. 2016 Oct;209(10):431-439. doi: 10.1016/j.cancergen.2016.08.007. Epub 2016 Sep 14. Cancer Genet. 2016. PMID: 27810071

9

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Leukemia. 2017 Sep;31(9):1995-1997. doi: 10.1038/leu.2017.180. Epub 2017 Jun 8. Leukemia. 2017. PMID: 28592886 No abstract available.

10

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C. Stengel A, et al. Among authors: haferlach t, haferlach c. Leukemia. 2018 Feb;32(2):295-302. doi: 10.1038/leu.2017.239. Epub 2017 Jul 28. Leukemia. 2018. PMID: 28751771

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page